CL2019001683A1 - Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. - Google Patents

Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.

Info

Publication number
CL2019001683A1
CL2019001683A1 CL2019001683A CL2019001683A CL2019001683A1 CL 2019001683 A1 CL2019001683 A1 CL 2019001683A1 CL 2019001683 A CL2019001683 A CL 2019001683A CL 2019001683 A CL2019001683 A CL 2019001683A CL 2019001683 A1 CL2019001683 A1 CL 2019001683A1
Authority
CL
Chile
Prior art keywords
activin
treatment
receptor antagonists
myostatin
obesity
Prior art date
Application number
CL2019001683A
Other languages
English (en)
Inventor
Tania Silvia Garito
Ronenn Roubenoff
Marjorie Zakaria
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2019001683A1 publication Critical patent/CL2019001683A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA O ANTAGONISTAS DE RECEPTOR PARA EL USO EN LA MEJORA DE LA COMPOSICIÓN CORPORAL, POR EJEMPLO, PARA EL TRATAMIENTO DE LA ADIPOSIDAD CENTRAL, LA OBESIDAD O LA CONDICIÓN DE SOBREPESO Y LAS COMORBILIDADES RELACIONADAS. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA O ANTAGONISTAS DE RECEPTOR PARA EL TRATAMIENTO DE LA DIABETES TIPO II, AL MEJORAR EL CONTROL GLUCÉMICO, EN PARTICULAR, AL AUMENTAR LA SENSIBILIDAD A LA INSULINA.
CL2019001683A 2016-12-21 2019-06-19 Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas. CL2019001683A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662437097P 2016-12-21 2016-12-21

Publications (1)

Publication Number Publication Date
CL2019001683A1 true CL2019001683A1 (es) 2019-09-13

Family

ID=60972283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001683A CL2019001683A1 (es) 2016-12-21 2019-06-19 Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.

Country Status (16)

Country Link
US (2) US20190345251A1 (es)
EP (1) EP3558361A1 (es)
JP (2) JP7280825B2 (es)
KR (1) KR20190097138A (es)
CN (1) CN110087684B (es)
AU (1) AU2017380844A1 (es)
BR (1) BR112019012661A2 (es)
CA (1) CA3042965A1 (es)
CL (1) CL2019001683A1 (es)
IL (1) IL267471A (es)
JO (1) JOP20190152A1 (es)
MX (1) MX2019007581A (es)
PH (1) PH12019501026A1 (es)
RU (1) RU2765288C2 (es)
TW (1) TWI812606B (es)
WO (1) WO2018116201A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015342936B2 (en) 2014-11-06 2020-10-08 Scholar Rock, Inc. Anti-pro/latent-Myostatin antibodies and uses thereof
EP3350220B1 (en) 2015-09-15 2021-05-19 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
EP3400240A2 (en) 2016-01-08 2018-11-14 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
WO2017218592A1 (en) 2016-06-13 2017-12-21 Scholar Rock, Inc. Use of myostatin inhibitors and combination therapies
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2944357T3 (es) 2017-01-06 2023-06-20 Scholar Rock Inc Tratamiento de enfermedades metabólicas inhibiendo la activación de miostatina
GB201706857D0 (en) * 2017-04-28 2017-06-14 Select Res Ltd Health risk prediction tools
JP7296408B2 (ja) 2018-06-18 2023-06-22 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤としてのピラゾール誘導体
BR112022003884A2 (pt) 2019-09-03 2022-05-31 Novartis Ag Tratamento de doença ou distúrbio hepático compreendendo antagonistas do receptor de actrii
US20240124541A1 (en) * 2021-04-12 2024-04-18 University of Florida Research Foundation, Incorprated Compositions and methods for treating obesity
AU2022299185A1 (en) * 2021-06-23 2024-01-25 Scholar Rock, Inc. A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
WO2023028606A1 (en) 2021-08-27 2023-03-02 Versanis Bio, Inc. Combination therapies
WO2024044782A1 (en) 2022-08-26 2024-02-29 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027071B1 (ru) 2009-04-27 2017-06-30 Новартис Аг АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
EP3845239A1 (en) * 2009-06-08 2021-07-07 Acceleron Pharma Inc. Use of anti-actriib proteins for increasing thermogenic adipocytes
CN107267520A (zh) * 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
EP2475427B1 (en) * 2009-09-09 2016-11-30 Acceleron Pharma, Inc. Actriib antagonists and dosing and uses thereof
PT2726099T (pt) * 2011-07-01 2018-11-13 Novartis Ag Método para o tratamento de distúrbios metabólicos
KR20150030706A (ko) * 2012-06-11 2015-03-20 암젠 인코퍼레이티드 이중 수용체 길항 항원-결합 단백질 및 그것의 사용
US20170260275A1 (en) * 2014-12-08 2017-09-14 Novartis Ag Myostatin or activin antagonists for the treatment of sarcopenia
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins
WO2017081624A1 (en) * 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof

Also Published As

Publication number Publication date
PH12019501026A1 (en) 2019-12-16
WO2018116201A1 (en) 2018-06-28
CA3042965A1 (en) 2018-06-28
TW201825120A (zh) 2018-07-16
CN110087684B (zh) 2023-12-01
RU2019119375A (ru) 2021-01-22
KR20190097138A (ko) 2019-08-20
US20190345251A1 (en) 2019-11-14
RU2765288C2 (ru) 2022-01-28
TWI812606B (zh) 2023-08-21
JOP20190152A1 (ar) 2019-06-20
RU2019119375A3 (es) 2021-01-29
MX2019007581A (es) 2019-09-04
IL267471A (en) 2019-08-29
AU2017380844A1 (en) 2019-05-16
CN110087684A (zh) 2019-08-02
US20210363263A1 (en) 2021-11-25
JP2023052026A (ja) 2023-04-11
JP2020511422A (ja) 2020-04-16
BR112019012661A2 (pt) 2020-01-28
EP3558361A1 (en) 2019-10-30
JP7280825B2 (ja) 2023-05-24

Similar Documents

Publication Publication Date Title
CL2019001683A1 (es) Antagonistas de miostatina, activina o receptor de activina para el uso en el tratamiento de la obesidad y afecciones relacionadas.
CL2020002796A1 (es) Derivados de gip y usos de estos
PE20210162A1 (es) Analogos de incretina y sus usos
CO2017003487A2 (es) Composiciones que comprenden polipéptidos gdf15 modificados para trastornos metabólicos
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
CR20150200A (es) Derivados de exendina-4 como agonistas duales de glp1/glucacón
CO7400885A2 (es) Análogos de glucagón
CL2014002556A1 (es) Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras.
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
AR098741A1 (es) Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón
MX2016013244A (es) Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon.
MX2016004907A (es) Analogos del glucagon.
AR102712A1 (es) Agonistas parciales del receptor de insulina
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
UY35233A (es) Derivados de Exendina-4 como agonistas dobles de GLP1/GIP o triples de GLP1/GIP/Glucagón
BR112019011228A2 (pt) compostos como agonistas do receptor de glp1/glucagon/gip trigonais peptídicos
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2016013248A (es) Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4.
UY36779A (es) Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CL2016002809A1 (es) Compuestos derivados de pirrol, piridina o piperidina sustituidos con heterociclos, moduladores del receptor acoplado a la proteína g 40 (gpr40); composición farmacéutica que los comprende; y su uso para el tratamiento de enfermedades como diabetes, retinopatía, neuropatía, aterosclerosis, obesidad e hipertensión.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
CR20190392A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CR20190393A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2020000812A1 (es) Semaglutida en la terapia médica.
CR20170376A (es) Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida